The FDA approved the expansion of Casgevy, which had previously been greenlit for patients 12 and up, into a younger pediatric population under the agency’s Commissioner’s National Priority Voucher program. The FDA has approved a pediatric expansion of Vertex Pharmaceuticals’ gene therapy Casgevy, allowing its use in children 2 years and up who have sickle cell disease and transfusion-dependent beta thalassemia. Casgevy is the first genetic medicine for these indications that can be used in yo

The Life Sciences category in PatSnap Open Platform MCP Servers Marketplace AI agents are changing how teams search, analyze, and act on information. But for life sciences teams, the real challenge is not only generating text — it is giving agents reliable access to specialized scientific, clinical, regulatory, and commercial intelligence. That is why PatSnap Open Platform is launching 12 Life Sciences MCP Servers: a new way for developers and innovation teams to connect life sciences intellig

Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Divarasib showed clinically meaningful improvements in progression-free survival compared to approved KRAS G12C inhibitors; no new safety signals were observed Statistical significance for overall survival was achieved at the interim analysis in this poor-prognosis patient population Data will be submitted to health authorities and presented at an upco

Financing brings together a syndicate of top-tier healthcare investors, including RA Capital Management, Leaps by Bayer, and Celea founder PureTech Health, alongside a large, US-based healthcare-focused fund and a leading sovereign wealth fund Proceeds will enable early Q3 2026 initiation of SURPASS-IPF, the first head-to-head Phase 3 trial in IPF, evaluating superiority of deupirfenidone vs. pirfenidone Celea Therapeutics ("Celea" or the "Company"), a clinical-stage biopharmaceutical company d

First gene replacement therapy in the EU for broad population with SMA, including children two years and older, teens and adults Fixed, one-time dose designed to replace the faulty SMN1 gene, providing a distinct option from ongoing dosing approaches Novartis gene replacement therapies now eligible in the EU for people with SMA across all age groups July 2, 2026 – Novartis today announced that the European Commission (EC) has approved Itvisma® (onasemnogene abeparvovec) for the treatment of chi

July 02, 2026 -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 clinical trials evaluating zoldonrasib, its oral RAS(ON) G12D-selective covalent inhibitor, in combination regimens for patients with RAS G12D metastatic pancreatic ductal adenocarcinoma (PDAC). The results, which will be presented today in a proffered paper session at the 2026 European

United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic cell therapies for the potential treatment of post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. The thymus is a critical organ for the development and proper function of key parts of the immune system, including training T-cells, which are essential for

Partillion Bioscience highlights new research underscoring Nanovial technology as an enabling platform for scalable functional cell-cell interaction datasets. July 2, 2026 -- A new Nature Biotechnology perspective article, authored by researchers from UCLA and collaborating institutions, is bringing renewed attention to cell-cell interaction data as an important missing layer for understanding complex biology and advancing foundation models in biology. Cell-cell interaction data captures how c

PureTech launches Celea as an independent company backed by a syndicate of top-tier healthcare investors, enabling PureTech’s transition to a lean operating model PureTech retains 35.4% ownership of Celea in addition to non-dilutive royalties, milestone payments, and sublicense income, maintaining long-term potential upside Proceeds enable Celea to initiate SURPASS-IPF, the first head-to-head Phase 3 trial in IPF, evaluating superiority of deupirfenidone as a potential new standard of care Pure

Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Divarasib showed clinically meaningful improvements in progression-free survival compared to approved KRAS G12C inhibitors; no new safety signals were observed Statistical significance for overall survival was achieved at the interim analysis in this poor-prognosis patient population Data will be submitted to health authorities and presented at an upcomi